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B 4.4 Surgery for Intermittent Claudication
B 4.4.1 Introduction
The most compelling indication for an open surgical revascularization procedure on the lower limb
is critical limb ischemia (rest pain, tissue loss). Therefore, surgical procedures are discussed in
greater breadth and depth in the section of the document dealing with CLI (Section D4,
Treatment of Critical Limb Ischemia, p S192). The following section addresses only the limited
application of surgical procedures appropriate to the treatment of patients with IC.
Surgery is rarely necessary in patients with IC; in fact, surgery should be avoided initially and other
options pursued in most patients. The generalized disease process present in patients with athero-
sclerotic occlusive disease is not benefited by limb revascularization, other than the relatively minor
considerations that increasing exercise capacity may improve conditioning and allow exercise thera-
py for angina. The overriding consideration is that, in the claudicant, the threat to life of general-
ized atherosclerosis takes priority over the limited threat to limb of the peripheral lesions. In a
non-limb-threatening situation, conservative treatment will provide sufficient improvement in
most, so the risk of both early and late complications associated with bypass grafting cannot be jus-
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tified. However, exceptional circumstances do exist, and these deserve discussion, for in practice,
valid exceptions to the general reservation against surgical revascularization may occur.
Ordinarily, if exercise therapy fails or is rejected by the patient for other reasons, these patients
may try pharmacotherapy or be referred for imaging to evaluate the possibility of balloon angio-
plasty. If these options are not possible, or fail, surgery may be considered. The decision to
involves an individualized risk:benefit analysis, balancing the benefit of relieving that particular
patient's disability against the immediate risks (morbidity/mortality/technical failure) and the
risk of late failure of the proposed surgical procedure. This weighing of risk and benefit must be
settled in the patient's favor.
B 4.4.2 Surgical Procedures
General considerations
Surgical procedures are discussed separately in terms of the results of their application to proxi-
mal or distal disease, the common femoral artery being the boundary. This is because not only is
the patency durability better for proximal disease but one often can treat both legs with the
same procedure. Even if a single-leg bypass does not fail, claudication may return because of
progression of like lesions in the contralateral extremity. The latter is not gauged by standard
outcome measures.
Continuing this comparison, distal procedures usually can be performed with a lower general and
systemic, but not local, morbidity rate than proximal procedures performed through abdominal
incisions. The use of prophylactic antibiotics has reduced the risk of graft infections to a rare but
disastrous occurrence, whose risk is increased if there is a groin incision.! Finally, although the
overall cardiac mortality/morbidity risk would seem intrinsically greater for those proximal recon-
structions involving aortic exposure and clamping, this is balanced by the fact that those with dis-
tal disease, specifically diabetic patients, generally have a higher prevalence of atherosclerotic
involvement of cardiac, renal, and other visceral circulations. Their perioperative risk is as high
and their survival worse than proximal reconstructions.cf Although these overall observations do
not apply specifically to patients with IC, a peripheral/distal procedure cannot be assumed to be
inherently less risky than a proximal one and thus easier to justify in a claudicant.
The patency rate for operations to treat inflow disease (aortoiliac occlusive disease) is also better
than that of femoropopliteal bypass. There are few direct comparative data in equivalent cases
indicating which type of bypass graft (extraanatomic vs anatomic, unilateral vs bilateral, and
bypass assisted by PTA) is the most appropriate in the patient suffering from IC.4,5 The choice
is generally based on arteriographic findings and patient risk, but most patients with IC who
would be accepted for bypass would be good risk with single-level disease. Given that, current
feeling is to perform the lesser operative procedure capable of producing high and durable
patency.
Proximal disease
With disease confined to the aortoiliac segments, the preferred operation is an aortofemoral
(usually bilateral) bypass or an extended endarterectomy.e-? The results of these procedures are
reasonably good, with an operative mortality rate of 1%to 4% and a 5-year patency of 85% to
Table 27: Patency at 5 and 10 years after aortobifemoral bypass
5y
Patency (range in sensith'ity)
----.
lOy
Limb-based claudication
Patient-based claudication
91.0 (90-94)
85.8 (85-89)
86.8 (85-92)
79.4 (78-83)
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90%, with the results tor patients with IC being on the better side of these ranges.f-? Modern
perioperative care has further improved the results and safety of the reference operation aortob-
ifemoral bypass, which allows treatment of both legs with a single operation and provides the
best durability. In a meta-analysis, De Vries and Huninkf reviewed 8,123 operations with an
operative mortality of 3.3%, and the patency rates for that subset of patients with claudication
were as shown (Table 27). This mortality rate applies to reported series dating back to 1975. It
can be presumed that the current mortality rate for claudicants undergoing proximal bypass is
closer to 1%than 2%.
Sexual dysfunction has been a concern in the operative treatment of proximal disease in sexually
active men, but by avoidance of the hypogastric plexus and selection of bypass based on careful
preoperative study of the arteriogram.U this type of complication can be minimized and sexual
function improved after proximal bypass. Improved results with respect to erectile dysfunction
have also been reported after endarterectomy.l2,13
Axillobifernoral bypass is an extra-anatomic bypass that reduces the risk of proximal reconstruc-
tion by avoiding an abdominal incision with aortic dissection and clamping. However, its prima-
ry patency is inferior to aortobifernoral bypass and, in spite of improving results, it is still not
recommended for the treatment of IC. In the case of unilateral iliac artery occlusion or exten-
sive disease within one iliac artery not amenable to PTA and stenting, there is a role for limited
procedures such as iliofemoral or crossover femorofemoral bypass grafts, the latter even in com-
bination with donor iliac artery dilatation, because they lessen operative morbidity while yield-
ing acceptable results. 14,l S,16 In fact, in the absence of distal, that is, superficial femoral artery
occlusion, which is the case with most patients with IC, fernorofernoral bypass carries a similar
patency to aortobifemoral bypass.'?
In summary, proximal bypasses in patients with IC offer primary patency rates in the 80% to
90% range, and, if the appropriate patient and bypass are matched, reasonable morbidity and
mortality rates (close to 1%). Their greater durability and degree of symptom relief may be a
reasonable trade-off for the immediate morbidity in active good-risk patients with IC whose aor-
toiliac lesions are not suitable for PTA and stent.
Distal disease
Extensive infrainguinal occlusive disease requiring bypass to infrapopliteal arteries, or to a
popliteal artery with significant runoff disease but causing only claudication, very rarely justifies
surgical intervention. In rare patients with extensive disease and severe claudication, there have
been reports of successful tibial bypass.l 8,l 9 If the disease is confined to 'the superficial femoral
artery and the distal vessels arc relatively disease free, bypass may be justified in selected patients,
following previously stated principles and strategies.
Controversy remains about the use of autogenous vein versus prosthesis in above-knee bypass.
The arguments are summarized in Table 28. Those favoring above-knee prosthetic bypass point
out that (1) patency is close enough to autogenous vein that most series fail to show statistically
significant difference and (2) it preserves vein for other, later uses. The opposing point ofview
insists that autogenous vein is better and should be used first and that other or later need for the
vein is only 5% to 10%.20 Because below-knee patency is better than above-knee patency for auto-
genous femoropopliteal bypass.I! this would favor bypass to the below-knee popliteal segment.l?
However, although the available data do not allow absolute recommendations, most surgeons
either would withhold surgery for such claudicators or use above-knee prosthetic bypass.
The evaluation of results for different grafts in patients with Ie is complicated by the fact that
most authors report success rates for a given operation with no substratification for indications
for operation. The combinations of procedures and variability of graft material inhibit the inter-
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Table 28: Benefits of vein versus prosthetic grafts for above-knee fernoropopliteal bypass
In favor ofvein
• Better long-term patency rates
• Avoidance of "staged" approach to femoral popliteal
reconstruction (ie, best operation first time)
• Other graft material (ie, internal mammary arteries) are
available for those patients requiring coronary artery bypass.
• Need for other use overestimated .
• Lower risk of graft infection
In favor ofprosthesis
• Close to equivalent long-term patency rates
• Better combined patency rates with prosthesis first, vein second
if the need for secondary reconstructions is considered
• Fewer wound complications
• Vein available for secondary or coronary bypass
• Shorter operative time
Table 29: Patency data for bypass grafts in patients with intermittent claudication-Z
5-yearprimary patency
Baseline Sensitivity analysis
Vein bypass
PTFE (above knee)
PTFE (below knee)
80 (2)
75 (3)
65 (6)
78-87
67-83
56-76
Critical Issue 16: Conduit for femoropopliteal bypass
There is a need for further studies to resolve the debate regarding the most appropriate
conduit for an above-knee femoral popliteal bypass.
pretation of patency data. For reconstruction of the aortoiliac segment, prosthetic material
(Dacron or expanded polytetrafluorethylene [ePTFE]) with or without external support is used
without clear preference. For infrainguinal reconstruction, possible graft materials include
ePTFE , glutaraldehyde-treated human umbilical vein [HUV), Dacron, and autologous vein
(Table 28) .22,23,24 Further discussion of these details is undertaken in D 4, Treatment of Critical
Limb Ischemia (p S192), but some comparative data are available for c1audicants. The best
patency data available come from the meta-analysis by Hunink et al,22 the data for IC being as
shown (Table 29) .
B 4.4.3 Summary: Surgery for Intermittent Claudication
To benefit from surgery, it is not only important that the patencies be high, but rather that
mortality and morbidity rates be kept low. Although it is generally accepted that surgical mortal-
ity should be less than 5% when dealing with both patients with IC and those with severe
ischemia, this should be significantly lower before considering surgery for claudication. One
must take into account that the expected 5-year survival rate for claudicants treated without
surgery is as high as 87%, an estimated risk of limb loss of only 1%per year, and a required
intervention rate of 6% per year for limb salvage.23 From the Swedish Vascular Registry, it has
recently been calculated that during the 10-year period 1987 to 1996, the combined mortality
and amputation rate was 2.2% for aortofemoral reconstruction, 1.4% for femoropopliteal recon-
struction, and 2 .0% for distal reconstructions, so results are improving.w This and patency rates
that are predictably 20% or more above those of PTA and stents for a given lesion will preserve
a role for surgical bypass in claudicants, albeit a very selective one.
Recommendation 37: Sur~ery for intermittent claudication
• Surgery should be offered to treat severe symptoms only after other forms of med-
ical therapy have been recommended and have either failed or been rejected for good
reason.
• If used, surgery for IC should employ the procedure offering extended clinical bene
fit, ie, one with a high benefit-to-risk ratio.
• If necessary, surgery is the treatment of choice of type D lesions but may be used
also in type Band C lesions (see Recommendation 32, p 598, and Critical Issue 10, p 598).
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Lumbar sympathectomy
No objective evidence supports the use of lumbar sympathectomy in the treatment ofIC.25
Neither resting nor exercise blood flow is increased by the performance of a sympathectomy.26
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B 4.5 Comparison of Therapeutic Options for Intermittent Claudication
There is overwhelming evidence that walking capacity is increased by exercise. The timing and
type of exercise has been extensively studied, and supervised frequent exercise sessions offer sig-
nificant benefit in increasing claudication distance (see B 4.1.2, Basic Treatment, p S80).1 The
